Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Mont...(Nine Months Ended ...),Health

Date:11/5/2009

Nine Months Ended September 30, ------------- 2009 2008 ---- ---- Operating activities: Net income $23,278 $26,006 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 2,583 878 Provision for doubtful accounts 2,240 2,280 Stock-based compensation expense 7,306 5,156 Excess tax benefits from stock-based compensation awards (3,403) (118) Amortization of premium (discount) on investment securities, net 458 (163) Deferred taxes (29) (9,519) Realized loss on sale of investment - 66 Loss (gain) on sale of property and equipment 6 (10) Changes in operating assets and liabilities: Accounts receivable (10,165) (9,629) Other current and long-term assets (713) (50) Accounts payable and accrued expenses 2,922 3,075 Accrued compensation 4,552 2,443 Income taxes 3,756 2,897 Deferred revenues 754 (37) Deferred rent 43 149 -- --- Net cash provided by operating activities 33,588 23,424
'/>"/>

SOURCE Genoptix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors